{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:18:59Z","timestamp":1792725539604,"version":"4.5.0"},"reference-count":68,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Until the late 1800s, drug development was a chance finding based on observations and repeated trials and errors. Today, drug development must go through many iterations and tests to ensure it is safe, potent, and effective. This process is a long and costly endeavor, with many pitfalls and hurdles. The aim of the present review article is to explore what is needed for a molecule to move from the researcher bench to the patients\u2019 bedside, presented from an industry perspective through the development program of cariprazine. Cariprazine is a relatively novel antipsychotic medication, approved for the treatment of schizophrenia, bipolar mania, bipolar depression, and major depression as an add-on. It is a D3-preferring D3-D2 partial agonist with the highest binding to the D3 receptors compared to all other antipsychotics. Based on the example of cariprazine, there are several key factors that are needed for a molecule to move from the researcher bench to the patients\u2019 bedside, such as targeting an unmet medical need, having a novel mechanism of action, and a smart implementation of development plans.<\/jats:p>","DOI":"10.3390\/ijms25115682","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T09:04:25Z","timestamp":1716455065000},"page":"5682","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["D3 Receptor-Targeted Cariprazine: Insights from Lab to Bedside"],"prefix":"10.3390","volume":"25","author":[{"given":"\u00c1gota","family":"Barab\u00e1ssy","sequence":"first","affiliation":[{"name":"Medical Division, Gedeon Richter Plc., 1103 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zs\u00f3fia Borb\u00e1la","family":"Dombi","sequence":"additional","affiliation":[{"name":"Medical Division, Gedeon Richter Plc., 1103 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"N\u00e9meth","sequence":"additional","affiliation":[{"name":"Medical Division, Gedeon Richter Plc., 1103 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Poduri, R. (2021). Drug Discovery and Development: From Targets and Molecules to Medicines, Springer.","DOI":"10.1007\/978-981-15-5534-3"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Ng, R. (2009). Drugs: From Discovery to Approval, John Wiley & Sons, Inc.","DOI":"10.1002\/9780470403587"},{"key":"ref_3","unstructured":"Mann, S.K., and Marwaha, R. (2024, May 16). Chlorpromazine, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK553079\/."},{"key":"ref_4","unstructured":"Bloom, F.E. (2024, May 16). Antianxiety Drug. Available online: https:\/\/www.britannica.com\/science\/antianxiety-drug."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4103\/0019-5545.82567","article-title":"Antidepressants: From MAOIs to SSRIs and More","volume":"53","author":"Ramachandraih","year":"2011","journal-title":"Indian J. Psychiatry"},{"key":"ref_6","unstructured":"(2024, May 16). The Drug Discovery Process: What Is It and Its Major Steps. Available online: https:\/\/blog.biobide.com\/the-drug-discovery-process."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S0140-6736(17)30181-2","article-title":"Schizophrenia, Primary Negative Symptoms, and Soft Outcomes in Psychiatry","volume":"389","author":"Leucht","year":"2017","journal-title":"Lancet"},{"key":"ref_8","unstructured":"Food and Drug Administration (2024, May 16). VRAYLAR (Cariprazine) Capsules Full Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/204370s009lbl.pdf."},{"key":"ref_9","unstructured":"European Medicinal Agency (2024, May 16). Reagila Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/reagila-epar-product-information_en.pdf."},{"key":"ref_10","unstructured":"(2024, May 16). U.S. FDA Approves VRAYLAR\u00ae (Cariprazine) as an Adjunctive Treatment for Major Depressive Disorder. Available online: https:\/\/news.abbvie.com\/news\/press-releases\/us-fda-approves-vraylar-cariprazine-as-an-adjunctive-treatment-for-major-depressive-disorder.htm."},{"key":"ref_11","unstructured":"Taylor, K., Properzi, F., Cruz, M.J., Ronte, H., and Haughey, J. (2024, May 16). Intelligent Clinical Trials Transforming through AI-Enabled Engagement. Available online: https:\/\/www2.deloitte.com\/us\/en\/insights\/industry\/life-sciences\/artificial-intelligence-in-clinical-trials.htmlials.htm."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12992-024-01019-x","article-title":"Pull Me\u2014Push You? The Disparate Financing Mechanisms of Drug Research in Global Health","volume":"20","author":"Matthey","year":"2024","journal-title":"Glob. Health"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1017\/S1744133112000321","article-title":"Neglected Infectious Diseases: Are Push and Pull Incentive Mechanisms Suitable for Promoting Drug Development Research?","volume":"8","year":"2013","journal-title":"Health Econ. Policy Law"},{"key":"ref_14","first-page":"9","article-title":"Some Theoretical and Practical Aspects of the Disturbances of Consciousness with Special Reference to Akinetic Mutism","volume":"3","year":"1988","journal-title":"Funct. Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"785592","DOI":"10.3389\/fpsyt.2022.785592","article-title":"Potential Mechanisms for Why Not All Antipsychotics Are Able to Occupy Dopamine D3 Receptors in the Brain in Vivo","volume":"13","author":"Kiss","year":"2022","journal-title":"Front. Psychiatry"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1021\/acsmedchemlett.1c00527","article-title":"Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia","volume":"13","author":"Heffernan","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/schbul\/sbac013","article-title":"Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia","volume":"48","author":"Davidson","year":"2022","journal-title":"Schizophr. Bull."},{"key":"ref_18","unstructured":"Chokhawala, K., and Stevens, L. (2024, May 16). Antipsychotic Medications, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK519503\/."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Grinchii, D., and Dremencov, E. (2020). Mechanism of Action of Atypical Antipsychotic Drugs in Mood Disorders. Int. J. Mol. Sci., 21.","DOI":"10.20944\/preprints202011.0143.v1"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"107704","DOI":"10.1016\/j.neuropharm.2019.107704","article-title":"Antipsychotics: Mechanisms Underlying Clinical Response and Side-Effects and Novel Treatment Approaches Based on Pathophysiology","volume":"172","author":"Kaar","year":"2020","journal-title":"Neuropharmacology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"781946","DOI":"10.3389\/fpsyt.2021.781946","article-title":"Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?","volume":"12","author":"Mohr","year":"2022","journal-title":"Front. Psychiatry"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1017\/S1092852918001013","article-title":"Beyond the Dopamine Hypothesis of Schizophrenia to Three Neural Networks of Psychosis: Dopamine, Serotonin, and Glutamate","volume":"23","author":"Stahl","year":"2018","journal-title":"CNS Spectr."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Potkin, S.G., Kane, J.M., Correll, C.U., Lindenmayer, J.P., Agid, O., Marder, S.R., Olfson, M., and Howes, O.D. (2020). The Neurobiology of Treatment-Resistant Schizophrenia: Paths to Antipsychotic Resistance and a Roadmap for Future Research. NPJ Schizophr., 6.","DOI":"10.1038\/s41537-019-0090-z"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"M\u00f8rup, M.F., Kymes, S.M., and \u00c5str\u00f6m, D.O. (2020). A Modelling Approach to Estimate the Prevalence of Treatment-Resistant Schizophrenia in the United States. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0234121"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Marder, S.R., Davidson, M., Zaragoza, S., Kott, A., Khan, A., Wang, X., Velligan, D.I., Umbricht, D., Luthringer, R., and Daniel, D. (2020). Issues and Perspectives in Designing Clinical Trials for Negative Symptoms in Schizophrenia: Consensus Statements. Schizophr. Bull. Open, 1.","DOI":"10.1093\/schizbullopen\/sgz001"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Soares Da Costa, I., and Moreira, R. (2022). Negative Symptoms\u2014A Real Unmet Need. Eur. Psychiatry, 65.","DOI":"10.1192\/j.eurpsy.2022.2044"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Galderisi, S., Riva, M.A., Girardi, P., Amore, M., Carpiniello, B., Aguglia, E., Fagiolini, A., Mucci, A., and Vita, A. (2020). Schizophrenia and \u201cUnmet Needs\u201d: From Diagnosis to Care in Italy. Eur. Psychiatry, 63.","DOI":"10.1192\/j.eurpsy.2019.8"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Lungu, P.F., Lungu, C.M., Ciobica, A., Balmus, I.M., Vitalaru, R., Mavroudis, I., Dobrin, R., Cimpeanu, M., and Gurzu, I.L. (2024). The Effect of Antipsychotics on Cognition in Schizophrenia\u2014A Current Narrative Review. Brain Sci., 14.","DOI":"10.3390\/brainsci14040359"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Harvey, P.D., Strassnig, M.T., and Silberstein, J. (2019). Prediction of Disability in Schizophrenia: Symptoms, Cognition, and Self-Assessment. J. Exp. Psychopathol., 10.","DOI":"10.1177\/2043808719865693"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/NDT.S225643","article-title":"Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment","volume":"16","author":"Correll","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1007\/s12325-021-01797-5","article-title":"Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety","volume":"38","author":"Laszlovszky","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(17)30060-0","article-title":"Cariprazine versus Risperidone Monotherapy for Treatment of Predominant Negative Symptoms in Patients with Schizophrenia: A Randomised, Double-Blind, Controlled Trial","volume":"389","author":"Laszlovszky","year":"2017","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/syn.890190102","article-title":"Dopamine D2 and D3 Receptors in the Rat Striatum and Nucleus Accumbens: Use of 7-OH-DPAT and [125I]-Iodosulpride","volume":"19","author":"Booze","year":"1995","journal-title":"Synapse"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0006-8993(91)91456-B","article-title":"Localization of Dopamine D3 Receptor MRNA in the Rat Brain Using in Situ Hybridization Histochemistry: Comparison with Dopamine D2 Receptor MRNA","volume":"564","author":"Bouthenet","year":"1991","journal-title":"Brain Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0893-133X(98)00066-9","article-title":"Distribution of Dopamine D3 Receptor Expressing Neurons in the Human Forebrain Comparison with D2 Receptor Expressing Neurons","volume":"20","author":"Gurevich","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00210-012-0797-0","article-title":"Direct and Indirect Interactions of the Dopamine D3 Receptor with Glutamate Pathways: Implications for the Treatment of Schizophrenia","volume":"386","author":"Sokoloff","year":"2013","journal-title":"Naunyn. Schmiedebergs. Arch. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5846","DOI":"10.1523\/JNEUROSCI.0310-17.2017","article-title":"D3 Receptors Regulate Excitability in a Unique Class of Prefrontal Pyramidal Cells","volume":"37","author":"Clarkson","year":"2017","journal-title":"J. Neurosci."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Torrisi, S.A., Geraci, F., Contarini, G., Salomone, S., Drago, F., and Leggio, G.M. (2022). Dopamine D3 Receptor, Cognition and Cognitive Dysfunctions in Neuropsychiatric Disorders: From the Bench to the Bedside, Springer.","DOI":"10.1007\/7854_2022_326"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Kiss, B., Laszlovszky, I., Kr\u00e1mos, B., Visegr\u00e1dy, A., Bobok, A., L\u00e9vay, G., Lendvai, B., and Rom\u00e1n, V. (2021). Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders. Biomolecules, 11.","DOI":"10.3390\/biom11010104"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Gurevich, E.V. (2022). Location, Location, Location: The Expression of D3 Dopamine Receptors in the Nervous System, Springer International Publishing.","DOI":"10.1007\/7854_2022_314"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1007\/s00213-016-4382-y","article-title":"Preferential Binding to Dopamine D3 over D2 Receptors by Cariprazine in Patients with Schizophrenia Using PET with the D3\/D2 Receptor Ligand [11C]-(+)-PHNO","volume":"233","author":"Girgis","year":"2016","journal-title":"Psychopharmacology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1358\/dot.2016.52.2.2461868","article-title":"Cariprazine: New Dopamine Biased Agonist for Neuropsychiatry Disorders","volume":"52","year":"2016","journal-title":"Drugs Today"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"9.14.1","DOI":"10.1002\/0471141755.ph0914s50","article-title":"Measuring Receptor Target Coverage: A Radioligand Competition Binding Protocol for Assessing the Association and Dissociation Rates of Unlabeled Compounds","volume":"50","author":"Sykes","year":"2010","journal-title":"Curr. Protoc. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1017\/S1092852917000608","article-title":"Drugs for Psychosis and Mood: Unique Actions at D3, D2, and D1 Dopamine Receptor Subtypes","volume":"22","author":"Stahl","year":"2017","journal-title":"CNS Spectr."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/ijnp\/pyy004","article-title":"Comparison of Dopamine D3 and D2 Receptor Occupancies by a Single Dose of Blonanserin in Healthy Subjects: A Positron Emission Tomography Study with [11C]-(+)-PHNO","volume":"21","author":"Tateno","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/archgenpsychiatry.2009.43","article-title":"The Effect of Antipsychotics on the High-Affinity State of D2 and D3 Receptors: A Positron Emission Tomography Study with [11C]-(+)-PHNO","volume":"66","author":"Mamo","year":"2009","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.schres.2011.05.005","article-title":"Effects of Antipsychotics on D3 Receptors: A Clinical PET Study in First Episode Antipsychotic Naive Patients with Schizophrenia Using [11C]-(+)-PHNO","volume":"131","author":"Mizrahi","year":"2011","journal-title":"Schizophr. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s40273-021-01065-y","article-title":"How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment","volume":"39","author":"Schlander","year":"2021","journal-title":"Pharmacoeconomics"},{"key":"ref_49","unstructured":"Thomas, D.W., Burns, J., Audette, J., Carroll, A., Dow-Hygelund, C., and Hay, M. (2016). Clinical Development Success Rates 2006\u20132015, Biotechnology Innovation Organization."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11920-021-01298-w","article-title":"New Antipsychotic Medications in the Last Decade","volume":"23","author":"Pahwa","year":"2021","journal-title":"Curr. Psychiatry Rep."},{"key":"ref_51","unstructured":"Park, B. (2024, May 17). Pimavanserin Fails to Meet Primary Endpoint in Schizophrenia Trial. Available online: https:\/\/www.empr.com\/home\/news\/drugs-in-the-pipeline\/pimavanserin-fails-to-meet-primary-endpoint-in-schizophrenia-trial\/."},{"key":"ref_52","unstructured":"Barrie, R. (2024, May 17). Minerva Hit with FDA Rejection for Schizophrenia Symptom Drug. Available online: https:\/\/www.pharmaceutical-technology.com\/news\/minerva-hit-with-fda-rejection-for-schizophrenia-symptom-drug\/."},{"key":"ref_53","unstructured":"(2024, May 16). National Institute on Aging What Are Clinical Trials and Studies?, Available online: https:\/\/www.nia.nih.gov\/health\/what-are-clinical-trials-and-studies."},{"key":"ref_54","unstructured":"(2024, May 16). World Health Organization Clinical Trials. Available online: https:\/\/www.who.int\/health-topics\/clinical-trials#tab=tab_1."},{"key":"ref_55","unstructured":"Food and Drug Administration (2024, May 17). Step 3: Clinical Research, Available online: https:\/\/www.fda.gov\/patients\/drug-development-process\/step-3-clinical-research."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.schres.2013.11.041","article-title":"An Evaluation of the Safety and Efficacy of Cariprazine in Patients with Acute Exacerbation of Schizophrenia: A Phase II, Randomized Clinical Trial","volume":"152","author":"Durgam","year":"2014","journal-title":"Schizophr. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bdi.12238","article-title":"The Efficacy and Tolerability of Cariprazine in Acute Mania Associated with Bipolar I Disorder: A Phase II Trial","volume":"17","author":"Durgam","year":"2015","journal-title":"Bipolar Disord."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.schres.2018.08.020","article-title":"Efficacy of Cariprazine on Negative Symptoms in Patients with Acute Schizophrenia: A Post Hoc Analysis of Pooled Data","volume":"204","author":"Earley","year":"2019","journal-title":"Schizophr. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.conctc.2018.08.001","article-title":"Factors Associated with Clinical Trials That Fail and Opportunities for Improving the Likelihood of Success: A Review","volume":"11","author":"Fogel","year":"2018","journal-title":"Contemp. Clin. Trials Commun."},{"key":"ref_60","unstructured":"Carpenter, D. (2024, May 16). Gatekeeping and the FDA\u2019s Role in Human Subjects Protection. Available online: https:\/\/journalofethics.ama-assn.org\/article\/gatekeeping-and-fdas-role-human-subjects-protection\/2004-11."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1001\/jama.2013.282542","article-title":"Scientific and Regulatory Reasons for Delay and Denial of FDA Approval of Initial Applications for New Drugs, 2000\u20132012","volume":"311","author":"Sacks","year":"2014","journal-title":"JAMA"},{"key":"ref_62","unstructured":"Alfano, S., Harputlugil, E., Lydon, J., Salazar, P., and Wells, C. (2024, May 16). Building a Global Biotech: Taking a First-Time Launch into International Markets. Available online: https:\/\/www.mckinsey.com\/industries\/life-sciences\/our-insights\/building-a-global-biotech-taking-a-first-time-launch-into-international-markets."},{"key":"ref_63","unstructured":"Cooper, D., and Gupta, V. (2024, May 17). Lumateperone, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560844\/."},{"key":"ref_64","unstructured":"Food and Drug Administration (2024, May 17). Improving the Design of Clinical Trials of Drugs to Treat Schizophrenia, Available online: https:\/\/www.fda.gov\/drugs\/regulatory-science-action\/improving-design-clinical-trials-drugs-treat-schizophrenia."},{"key":"ref_65","unstructured":"European Medicinal Agency (2024, May 17). Clinical Investigation of Medicinal Products, Including Depot Preparations in the Treatment of Schizophrenia\u2014Scientific Guideline, Available online: https:\/\/www.ema.europa.eu\/en\/clinical-investigation-medicinal-products-including-depot-preparations-treatment-schizophrenia-scientific-guideline."},{"key":"ref_66","unstructured":"Food and Drug Administration (2024, May 17). Real-World Evidence, Available online: https:\/\/www.fda.gov\/science-research\/science-and-research-special-topics\/real-world-evidence."},{"key":"ref_67","unstructured":"Garijo, B. (2024, May 17). What to Expect from the next Decade of Drug Development. Available online: https:\/\/www.weforum.org\/agenda\/2020\/02\/technology-in-drug-discovery-and-development\/."},{"key":"ref_68","unstructured":"(2024, May 17). StartUs Insights Explore the Top 9 Drug Development Trends in 2024. Available online: https:\/\/www.startus-insights.com\/innovators-guide\/drug-development-trends-innovation\/."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/11\/5682\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:47:14Z","timestamp":1760107634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/11\/5682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":68,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["ijms25115682"],"URL":"https:\/\/doi.org\/10.3390\/ijms25115682","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,23]]}}}